Oncolytics Biotech Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/23/2026)
| Balance Sheet | Total Assets | 7,582,000.00 | ROE | -50.11 % |
| Balance Sheet | Total Equity | -3,799,000.00 | ROA | -379.31 % |
| Cashflow | Capital Expenditures | -6,000.00 | P/FCF | -2.56 |
| Cashflow | Free Cash Flow | -27,596,278.00 | – | – |
| Cashflow | Operating Cash Flow | -27,596,278.00 | P/CF | -2.56 |
| Income | Earnings per Share (diluted) | -0.29 | Div. Yield | – |
| Income | Net Income | -39,461,086.00 | P/E | -1.79 |
| Income | Shares Outstanding | 108,021,271.00 | P/B | -13.57 |
| Income | Total Revenue | 5,343,033,000.00 | P/S | 0.01 |
Ratios calculated on: 10/14/2026
Company Description
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.oncolyticsbiotech.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more